Cellectis Receives FDA RMAT Status for lasme-cel – First Allogeneic CAR-T in Pivotal Trial for r/r B-ALL

Cellectis got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access.